

Review Form 1.7

Journal Name:	Journal of Advances in Medicine and Medical Research
Manuscript Number:	Ms_JAMMR_100484
Title of the Manuscript:	Role of TPA, Streptokinase, and other thrombolytics in the treatment of myocardial infarction
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljammr.com/index.php/JAMMR/editorial-policy>)

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p>1 yes</p> <p>This MS discusses some important issues and challenges in modern Acute Coronary Syndrome (ACS) management and highlights the role of thrombolytics in the treatment of myocardial infarction (MI). However, in its current form, the MS requires a revision. The authors may consider some suggestions for improvement.</p> <p>2 a suggested alternative title:</p> <p>Role of tissue plasminogen activators, streptokinase, and other thrombolytics in the treatment of myocardial infarction</p> <p>3 fair</p> <p>4 fair</p> <p>5 yes</p> <p>6 some new ref., e.g.,</p> <p>Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327(7):662-675.</p> <p>Collet JP, Thiele H, Barbato E, et al., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.</p> <p><u>additional suggestions/comments</u></p> <p>At the end of the Introduction, the authors need to include the aim of this review.</p> <p>A section: 'The Evolution of Thrombolytic Therapy: A Historical Perspective' should be placed after the Introduction.</p> <p>A table presenting clinically relevant results of the main RCTs in this area would be helpful for the readers.</p> <p>A section: 'Clinical Recommendations' should be updated [e.g., by using the 2020 ESC Guidelines for the management of acute coronary syndromes].</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>	<p>English language quality of the article needs to be improved.</p> <p>In the entire MS, the phrase: 'STEMI patients' should be replaced by: 'patients with STEMI'.</p> <p>The authors need to explain some abbreviations in the entire text and provide a list of abbreviations at the end.</p>	
<p>Optional/General comments</p>	<p>As above</p>	

Review Form 1.7

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Katarzyna Rygiel
Department, University & Country	Medical University of Silesia, Poland